Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Reid-Rowell's Rowasa (mesalamine) suppository

Executive Summary

New dosage form is now being promoted by sales reps and advertised in gastroenterology journals. Shipments to wholesalers of the 500 mg suppository product began on Jan. 7. The suppository was approved Dec. 18 for treatment of active ulcerative proctitis. The Rowasa suspension enema, approved in December 1987 for treatment of active mild-to-moderate distal ulcerative colitis, proctosigmoiditis or proctitis, was the first 5-ASA product to enter the market.
Advertisement
Advertisement
UsernamePublicRestriction

Register

PS018777

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel